Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDGLMadrigal Pharmaceuticals$539.09-2.0%$512.65$286.44▼$615.00$12.43B-1.05348,053 shs103,376 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDGLMadrigal Pharmaceuticals+2.49%-2.68%+10.10%+4.86%+76.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDGLMadrigal Pharmaceuticals$539.09-2.0%$512.65$286.44▼$615.00$12.43B-1.05348,053 shs103,376 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDGLMadrigal Pharmaceuticals+2.49%-2.68%+10.10%+4.86%+76.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDGLMadrigal Pharmaceuticals 2.78Moderate Buy$687.9327.61% UpsideCurrent Analyst Ratings BreakdownLatest MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026MDGLMadrigal Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/11/2026MDGLMadrigal Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$550.00 ➝ $542.006/1/2026MDGLMadrigal Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOverweight6/1/2026MDGLMadrigal Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/13/2026MDGLMadrigal Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$640.00 ➝ $709.005/7/2026MDGLMadrigal Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$649.005/7/2026MDGLMadrigal Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$587.00 ➝ $578.005/6/2026MDGLMadrigal Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$620.004/21/2026MDGLMadrigal Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDGLMadrigal Pharmaceuticals$958.40M12.97N/AN/A$26.54 per share20.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDGLMadrigal Pharmaceuticals-$288.28M-$12.80N/A64.41N/A-27.32%-50.15%-25.44%8/4/2026 (Estimated)Latest MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026MDGLMadrigal Pharmaceuticals-$2.7620N/AN/AN/A$349.80 millionN/A5/6/2026Q1 2026MDGLMadrigal Pharmaceuticals-$3.61-$3.25+$0.36-$3.25$301.05 million$311.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDGLMadrigal Pharmaceuticals0.633.503.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipMDGLMadrigal Pharmaceuticals17.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDGLMadrigal Pharmaceuticals9023.06 million19.00 millionOptionableMDGL HeadlinesRecent News About These CompaniesMadrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026July 16 at 8:00 AM | globenewswire.comCalamos Advisors LLC Has $1.83 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGLJuly 16 at 4:23 AM | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (MDGL) and Krystal Biotech (KRYS)July 15 at 1:18 PM | theglobeandmail.comBrokerages Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) PT at $687.93July 15 at 4:01 AM | americanbankingnews.comEmerald Mutual Fund Advisers Trust Has $8.64 Million Position in Madrigal Pharmaceuticals, Inc. $MDGLJuly 14 at 4:15 AM | marketbeat.comMDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Pipeline MovesJuly 13 at 9:10 PM | finance.yahoo.comMadrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP PortfolioJuly 13 at 8:00 AM | globenewswire.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from AnalystsJuly 12, 2026 | marketbeat.comCandriam S.C.A. Increases Position in Madrigal Pharmaceuticals, Inc. $MDGLJuly 11, 2026 | marketbeat.comBofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)July 8, 2026 | insidermonkey.comMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | globenewswire.comMadrigal Pharmaceuticals, Inc. $MDGL Position Reduced by SG Americas Securities LLCJuly 4, 2026 | marketbeat.comRibo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASHJuly 2, 2026 | prnewswire.comRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHJuly 1, 2026 | prnewswire.comMadrigal Pharmaceuticals (MDGL) Receives a Buy from JefferiesJuly 1, 2026 | theglobeandmail.comPictet Asset Management Holding SA Raises Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGLJune 29, 2026 | marketbeat.comAssenagon Asset Management S.A. Purchases 10,643 Shares of Madrigal Pharmaceuticals, Inc. $MDGLJune 29, 2026 | marketbeat.comMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)June 22, 2026 | globenewswire.comGroupama Asset Managment Boosts Stake in Madrigal Pharmaceuticals, Inc. $MDGLJune 19, 2026 | marketbeat.comJanus Henderson Group PLC Has $918.20 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGLJune 18, 2026 | marketbeat.comMadrigal Pharmaceuticals, Inc. $MDGL is Armistice Capital LLC's 5th Largest PositionJune 18, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDGL Company DescriptionsMadrigal Pharmaceuticals NASDAQ:MDGL$539.09 -11.16 (-2.03%) As of 02:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Why Conagra’s Dividend Cut Could Be the Best Thing for Investors Which Storage Stock Is Best Positioned to Win the AI Memory War? Cintas Keeps Beating Expectations—And the Story Isn’t Over Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
